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The identiﬁcation of cancer-promoting genetic alterations is challenging particularly in highly
unstable and heterogeneous cancers, such as esophageal adenocarcinoma (EAC). Here we
describe a machine learning algorithm to identify cancer genes in individual patients con-
sidering all types of damaging alterations simultaneously. Analysing 261 EACs from the
OCCAMS Consortium, we discover helper genes that, alongside well-known drivers, promote
cancer. We conﬁrm the robustness of our approach in 107 additional EACs. Unlike recurrent
alterations of known drivers, these cancer helper genes are rare or patient-speciﬁc. However,
they converge towards perturbations of well-known cancer processes. Recurrence of
the same process perturbations, rather than individual genes, divides EACs into six clusters
differing in their molecular and clinical features. Experimentally mimicking the alterations of
predicted helper genes in cancer and pre-cancer cells validates their contribution to disease
progression, while reverting their alterations reveals EAC acquired dependencies that can be
exploited in therapy.
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Genome instability enables the onset of several hallmarks ofcancer with some acquired alterations conferring selectiveadvantages to the mutated cells and driving their out-
growth and eventual dominance1. The identiﬁcation of driver
genes (genes acquiring driver alterations) is therefore critical to
fully understand the molecular determinants of cancer and to
develop precision oncology. Since driver genes are under positive
selection during cancer progression, a reasonable assumption is
that their mutation is observed more frequently than expected. In
recent years, large-scale cancer genomic studies have provided the
required power to detect driver events recurring across samples
with good statistical conﬁdence2,3. However, the full character-
isation of driver events is challenging when a cancer’s genomic
landscape is highly variable and recurrent events are rare.
One such cancer is esophageal adenocarcinoma (EAC), whose
incidence in recent years has risen substantially in the western
world4. EAC exhibits high mutational and chromosomal
instability leading to widespread genetic heterogeneity. In over
400 EACs sequenced so far, mutations in TP53, CDKN2A,
SMARCA4, ARID1A, SMAD4, ERBB2, MYD88, PIK3CA, KAT6A,
ARID2, as well as ampliﬁcations of VEGFA, ERBB2, EGFR,
GATA4/6, CCNE1 are the most recurrent driver events5,6. How-
ever, a signiﬁcant fraction of patients remain without known
genetic determinants and the number of identiﬁed drivers per
sample is too low to fully explain the disease. Consequently, the
molecular mechanisms that drive EAC have been difﬁcult to
characterise in full. This impacts EAC diagnosis and treatment,
with recent phase III clinical trials of targeted agents failing to
show beneﬁts or reaching inconclusive results7,8.
Here we hypothesise that, alongside the critical role of recur-
rent and well-known drivers, complementary somatic alterations
of other genes help cancer progression in individual patients.
Therefore, the comprehensive characterisation of the full com-
pendium of cancer drivers requires that both recurrent and rare
events are considered. While recurrent drivers can be identiﬁed
based on the frequency of their alterations, rare genes altered in
few or even single patients are difﬁcult to identify. To this aim, we
develop sysSVM, an algorithm based on supervised machine
learning that predicts cancer genes in individual patients. The
rationale of sysSVM is that somatic alterations sustaining cancer
affect genes with speciﬁc properties9. It therefore uses these
properties, rather than recurrence, to identify cancer genes.
We apply sysSVM to 261 EACs from the UK OCCAMS
Consortium, part of the International Cancer Genome Con-
sortium (ICGC). We ﬁrst train the classiﬁer using 34 features
derived from the biological properties speciﬁc to known cancer
genes and then prioritise 952 genes that, together with the known
drivers, help promote cancer development across the whole EAC
cohort. The large majority of these newly predicted ‘helper’ genes
are rare or patient-speciﬁc but they converge towards the per-
turbation of cancer-related processes including intracellular sig-
nalling, cell cycle regulation, proteasome activity and Toll-like
receptor signalling. We use the recurrence of process perturba-
tion, rather than genes, to stratify the 261 EACs into six clusters
that show distinct molecular and clinical features and suggest
differential response to targeted treatment.
Results
The landscape of recurrent and rare EAC genes. sysSVM applies
machine learning to predict altered genes contributing to cancer
in individual patients based on the similarity of their molecular
and systems-level properties to those of known cancer genes
(Supplementary Note 1). Molecular properties include somatic
alterations with a predicted damaging effect on the protein
function (gene gains and losses, translocations, inversions,
insertions, truncating and non-truncating damaging alterations
and gain of function mutations) as well as the overall mutation
burden and the gene copy number (Supplementary Table 1).
Systems-level properties are genomic, epigenomic, evolutionary,
network and gene expression features that distinguish cancer
genes from other genes. They include gene length and protein
domain organisation9,10, gene duplicability11,12, chromatin
state13, connections and position in the protein-protein interac-
tion network11, number of associated regulatory miRNAs12, gene
evolutionary origin12 and breadth of gene expression in human
tissues9,10 (Supplementary Table 1).
sysSVM is composed of three steps (Fig. 1a, Supplementary
Note 1). In step 1, 34 features describing the gene molecular and
systems-level properties are mapped to all genes in each patient.
In step 2, known cancer genes altered in the patient cohort are
used to run a set of three-fold cross validations and identify the
best models in four kernels (linear, sigmoid, radial, polynomial).
In step 3, these best models are used for training and prediction.
All altered genes except the known cancer genes used for training
are ﬁrst scored in each patient individually by combining the
predictions of the four kernels and then ranked according to
the resulting score. Since the hypothesis is that the strength of the
contribution of a gene to cancer depends on how similar its
properties are to those of known cancer genes, the top scoring
genes in each patient are the most likely contributors to cancer
progression. The overall results are combined to obtain the ﬁnal
list of predicted cancer genes.
We applied sysSVM to 261 EACs from OCCAMS, which are
part of the ICGC dataset (Fig. 1b, Supplementary Data 1). In step
1, we extracted 17,078 genes with predicted damaging alterations
(median of 382 damaged genes per patient) and mapped their 34
features. We veriﬁed that there is no pairwise correlation between
these features (Supplementary Fig. 1). Moreover, 476 known
cancer genes14 altered in the 261 EACs (Supplementary Data 2)
tend to cluster in distinct regions of the feature space
(Supplementary Fig. 2). This conﬁrms that these features
distinguish cancer genes from other genes. In step 2, we ran
10,000 iterations of a three-fold cross validation using the 476
known cancer genes and combined the results to obtain 500 best
models for each kernel (Supplementary Table 2, Methods). In
step 3, we trained the four classiﬁers with these best models and
used them to score and rank the remaining 16,602 altered genes
in each patient. Since the gene score reﬂects a gradient between
driver and passenger activity, we considered the top 10 scoring
genes in each EAC as the main cancer contributors for that
patient. We veriﬁed that the main ﬁndings of our study hold true
if we apply higher or lower cut offs (see below). Overall, this
produced 500 lists of top 10 scoring genes in each sample
(Supplementary Table 2, Methods). We considered the list of 952
genes that occurred most frequently as the ﬁnal set of predicted
cancer genes (Supplementary Data 3). Since our hypothesis is that
these genes help the known drivers to promote cancer, we deﬁne
them as helper genes.
We investigated the importance of each feature in the four
classiﬁers by ranking the 34 features based on their weight15 and
observed interesting properties of the four models. Firstly,
categorical features were the top contributors for linear kernels
(linear and polynomial), while both categorical and continuous
features contributed to non-linear kernels (radial and sigmoid,
Supplementary Fig. 3). This likely reﬂects intrinsic differences
across kernels, and supports their integration to capture different
regions of the feature space and increase the chances of
identifying rare helpers. Secondly, no feature had zero weight in
all four kernels, indicating that all features contributed to the ﬁnal
gene classiﬁcation. Thirdly, despite the high prevalence of copy
number gains (Supplementary Table 1), gene ampliﬁcation was
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not the highest-ranking feature in any kernel (Supplementary
Fig. 3). We next checked whether nodes with similar topological
properties in the protein-protein interaction network had similar
functional properties, since this may bias the ﬁnal classiﬁcation. A
pathway enrichment analysis of the 2608 central hubs of the
network resulted in 528 enriched pathways (FDR= 0.01),
representing 46% of all Reactome pathways. This indicates a
large diversity in the functions of central hubs and excludes that
nodes with similar topological properties necessarily have similar
functional properties. Furthermore, a pathway enrichment
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analysis only considering 252 central hubs encoded by known
cancer genes resulted in 158 enriched pathways (FDR= 0.01). Of
these, 135 are in common with all central hubs, indicating that
cancer-related functions constitute a small fraction of pathways
enriched in central hubs.
Helper genes localise to the same high-density regions of
known cancer genes (Fig. 1c), with lower scoring genes being
further away (Supplementary Fig. 3). The properties of top
scoring genes therefore resemble those of known cancer
genes. Consistent with the prevalence of gene ampliﬁcation in
EAC (Supplementary Table 1), the vast majority of the 952
helpers undergo copy number gain (Fig. 1d), resulting in
their increased expression (Fig. 1e). Although prevalent gene
ampliﬁcation does not bias the best models (Supplementary
Fig. 3), we investigated its impact on the ﬁnal predictions. First,
only a minority of all ampliﬁed genes in the 261 EACs
are predicted as helper genes (Supplementary Fig. 4). Second,
the 952 ﬁnal helpers are ampliﬁed 6296 times in the 261 EACs,
but they are only predicted as helpers 2062 times (Supplementary
Fig. 4). Therefore, gene ampliﬁcation alone is not sufﬁcient for a
gene to be predicted as a helper. Despite the majority of
helpers being rare or patient-speciﬁc (Fig. 1f), some are altered in
over 10% of EACs (Supplementary Data 3) and are usually
associated with frequently occurring ampliﬁcations16 (Supple-
mentary Fig. 4).
We next assessed the robustness of our predictions. First, we
evaluated the performance of sysSVM using two independent
cohorts, 86 EACs from The Cancer Genome Atlas (TCGA) and
21 EACs from another study17 (Supplementary Data 1). We
scored all altered genes, including known cancer genes14, in each
of the 107 EACs independently, using the four best models
trained on the ICGC cohort. In both datasets, known cancer
genes have signiﬁcantly higher scores than the rest of the altered
genes (Supplementary Fig. 3), indicating that sysSVM is able to
recognise them as major cancer contributors. Second, we checked
whether any of the 952 helpers were previously identiﬁed as
cancer genes. We found that 41 helpers (4%) have recently been
added to the Cancer Gene Census14 and 171 helpers (18%) have
been predicted as candidate cancer genes in various cancers,
including EAC5 (Supplementary Data 3). Third, we searched for
possible false positive predictions using two lists. The ﬁrst was
composed of 49 genes predicted as false positives of recurrence-
based methods5 and contained only three helpers (PCLO,
CNTNAP2 and NRXN3; Supplementary Data 3). Interestingly,
PCLO has recently been shown to exert an oncogenic role in
esophageal cancer by interfering with EGFR signalling18. The
second list was a manually curated set of 488 putative false
positives3 and contained 44 helpers (4.6% of the total). This is less
than the fraction of known cancer genes14 present in the same list
of false positives (46/719, 6.4%). Altogether these analyses
indicate that sysSVM robustly predicts cancer genes in multiple
patient cohorts, with a minimal false positive rate.
Helper genes perturb cancer-related biological processes. To
gather a comprehensive characterisation of the molecular deter-
minants of EAC, we analysed the biological processes perturbed
by helpers compared to drivers. We manually reviewed the 476
known cancer genes14 with damaging alterations in the OCCAMS
cohort and retained 202 of them based on the concordance
between the type of acquired modiﬁcation and literature evidence
of their role as oncogenes or tumour suppressors (Supplementary
Data 2). The median number of drivers per EAC is in accordance
with recent estimates19, with a prevalence of gene ampliﬁcation
(Supplementary Fig. 4). We then performed two independent
gene set enrichment analyses, with either 202 known drivers or
952 helpers, to dissect their relative functional contribution to
EAC. This led to 212 and 189 enriched pathways out of the 1877
tested, respectively (FDR < 0.01, Supplementary Data 4, Supple-
mentary Fig. 4). The analysis of known drivers resulted in a
higher number of enriched pathways than helpers, despite their
lower number. This reﬂects the higher number of pathways that
drivers map to (median of four pathways for drivers and two
pathways for helpers).
Seventy-three pathways (over 34%) enriched in known drivers
are perturbed in over 50% of EACs (Supplementary Data 4,
Supplementary Fig. 5). These universal cancer pathways are
involved in well-known cancer-related processes, including
intracellular signalling, cell cycle control, apoptosis and DNA
repair, and are associated with the most recurrently altered
known drivers (TP53, CDKN2A, MYC, ERBB2, SMAD4, CDK6,
KRAS; Supplementary Data 2). Interestingly, 50 of the 73 (70%)
are also enriched in helpers and 86 patients with altered helpers in
a universal cancer pathway have no known drivers in that
pathway (Fig. 2a, Supplementary Data 4). This indicates that
helpers often contribute to the perturbation of key cancer
pathways and that their alteration may be sufﬁcient for cancer
development in the absence of known drivers.
Next, we clustered EACs according to the proportion of shared
perturbed pathways (Methods, Fig. 2b). When using pathways
enriched in known drivers, we identiﬁed ﬁve well-supported
clusters (1D-5D, Fig. 2c, median silhouette score= 0.5, Supple-
mentary Fig. 6). These clusters are clearly driven by the
mutational status of the most recurrent drivers. For example,
TP53 is altered in clusters 1D-3D, EGFR, ERBB2 and MYC are
altered in cluster 1D andMYC and KRAS are altered in cluster 2D
(Fig. 2d, Supplementary Data 1). Samples in clusters 4D and 5D
show an overall lower mutational burden (p= 0.03, Wilcoxon
rank sum test), fewer known drivers and consequently a lower
number of enriched pathways (p= 7 × 10–6, Wilcoxon rank
sum test).
Fig. 1 Cancer helper genes in 261 EACs. a Schematic workﬂow of the sysSVM algorithm. b Application of sysSVM to 261 EACs. Genes with somatic
damaging alterations (n= 116,989) were extracted from 261 EACs and divided into training (known cancer genes, blue) and prediction (rest of altered
genes, purple) sets. sysSVM was trained on the properties of known drivers and the best models were used for prediction. All altered genes were scored in
each patient individually and the top 10 hits were considered as the cancer helper genes in that patient, for a total of 2608 helper alterations, corresponding
to 952 unique hits (red). c t-distributed Stochastic Neighbour Embedding (t-SNE) plot of 116,989 altered genes in 261 EACs. Starting from the 34 properties
used in sysSVM, a 2-D map of the high-dimensional data was built using Rtsne package (https://github.com/jkrijthe/Rtsne) in R. Curves are coloured
according to the density of 476 known cancer genes altered 4091 times (blue) used as a training set and the rest of altered genes are coloured according to
their sysSVM score. d Distribution of damaging alterations in 952 cancer helpers. Overall, these genes acquire 2608 damaging alterations. e Expression of
helper genes in EACs where they are ampliﬁed compared to EACs where they are copy number neutral. FPKM values from RNA-Seq were available from
92 EACs. Out of the 952 helper genes, 389 had at least one ampliﬁcation across these samples, for a total of 751 ampliﬁcation events. Signiﬁcance was
assessed using the Wilcoxon rank-sum test. Lower and upper hinges and middle line of boxplots correspond to 25th, 75th, and 50th percentiles. Upper and
lower whiskers extend less than 1.5 times the interquartile range. f Recurrence of cancer helpers across 261 EACs. Only samples acquiring alterations with a
damaging effect are considered
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Fig. 2 Perturbed processes in 261 EACs. a Scatterplot of 51 universal pathways enriched in known drivers and helpers. For each pathway, the number of
EACs with altered drivers and the number of EACs with altered drivers and helpers is shown. The size of dots is proportional to the additional EACs with
perturbations in these pathways because of altered helpers only. b Schematic of the procedure to cluster EACs according to pathways enriched in known
drivers or helpers. Enriched pathways are mapped to individual EACs and the Jaccard index is calculated as the proportion of shared pathways over the
total pathways in each pair of samples (i, j). Hierarchical clustering is then performed. c Clustering of 261 EACs according to pathways enriched in known
drivers and helpers. Five clusters were identiﬁed using known drivers (1D-5D) and six using helpers (1H-6H). Cluster-matching coloured lines show where
EACs clustered by pathways enriched in helpers map in the driver clusters. d Mutational status of selected known drivers across 261 EACs. Drivers
enriched in clusters of helpers are highlighted. Signiﬁcance was assessed using the Fisher’s exact test, after correcting for False Discovery Rate (FDR)
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When clustering EACs according to the pathways enriched in
helpers, we identiﬁed six well-supported clusters (1H-6H, Fig. 2c,
median silhouette score= 0.3, Supplementary Fig. 6). Here,
samples are brought together not by the recurrent alterations of
the same helpers, but by different helpers mapping to the same or
related pathways (Supplementary Data 1). For example, both
clusters 1H and 3H show diffuse perturbations in intracellular
signalling (Fig. 2c), often involving universal cancer pathways
(Supplementary Data 4, Supplementary Fig. 7). In over 43% of
EACs in both clusters, perturbations in universal cancer pathways
occur in patients with no drivers. Other pathways perturbed in
cluster 1H, but not in 3H, involve cell cycle regulation, Toll-like
receptor signalling and proteasome activity (Supplementary
Data 1, Supplementary Fig. 7). EACs in cluster 1H are also
signiﬁcantly associated with several known drivers including
RECQL4, RARA, MYC, SMARCE1 and ERBB2 (Fig. 2d), which
are often but not always co-altered (Supplementary Fig. 4). They
have a prevalence of mutational signature S3 and are enriched in
early (stage 2) tumours (Fig. 3a). Patients in cluster 3H are
instead enriched in tobacco smokers (Fig. 3a).
The processes perturbed in clusters 2H and 4H are also
functionally related, in this case to cell cycle regulation (Fig. 2c).
All EACs in cluster 2H have helpers involved in the regulation of
the G1/S transition (Supplementary Fig. 7), including members of
the E2F family of transcription factors and associated co-
activators, competitors and downstream targets (Supplementary
Data 1). Cluster 4H instead harbours perturbations in DNA
replication, with alterations in the MCM complex, a downstream
target of E2F20. Dysregulation of E2F transcription factors or the
MCM complex can induce genomic instability through either
aberrant cell-cycle control or replicative stress21. Indeed, EACs in
clusters 2H accumulate signiﬁcantly more damaged and ampliﬁed
genes, while those in 4H show signiﬁcantly more deletions and
are enriched in mutational signature 2 (Fig. 3a). Cluster 2H also
shows signiﬁcant alterations of the known drivers GNAS, SS18L1,
and FHIT (Fig. 2d). FHIT is linked to increased genomic
instability22 and regulates the expression of cell cycle-related
genes23, therefore potentially affecting the G1/S transition
pathways of this cluster. Cluster 4H shows frequent alterations
in the known drivers TRAPP and CDK6 (Fig. 2d). The latter
functions in various cell cycle-related pathways, including the
mitotic G1/S phase pathway altered in 100% of cluster 4H
(Supplementary Data 1, Supplementary Fig. 7). Interestingly,
elevated expression of the MCM complex has been associated
with tumour aggressiveness and poor outcome24. Their perturba-
tion could therefore explain the signiﬁcantly lower survival
observed for patients in cluster 4H (Fig. 3b). Finally, cluster 5H
shows perturbations in the Toll-like receptor (TLR) signalling
cascade (Supplementary Fig. 7) that has recently been linked to
EAC25.
Overall, clusters 1H to 5H account for 166 EACs (64% of the
total cohort). The remaining 95 EACs in cluster 6H share fewer
perturbed pathways, although 55 of them (58%) have alterations
in Rho GTPase activity (Supplementary Fig. 7) with frequent
modiﬁcations of Rho GTPase effectors including ROCK1, PTK2,
PAK1, LIMK1 and NDE1 (Supplementary Data 1). EACs in the
six clusters obtained using helpers are broadly dispersed in the
clustering of known drivers (Fig. 2c) indicating that helpers bring
together patients with similar perturbed processes that cannot be
appreciated when focussing only on recurrent drivers.
To test whether the germline genetic makeup of EAC patients
was associated with the somatic perturbation of speciﬁc processes,
we identiﬁed patients with potentially damaging germline
variants in 152 known cancer predisposition genes26. Overall,
we found 82 patients with damaging variants in 54 predisposition
genes, with no signiﬁcant enrichment compared to European
controls27 (Supplementary Fig. 8). This is expected since
the heritable component of EAC is spread over a large number
of low-impact loci28. We then tested for associations
between cancer predisposition genes and clusters of helpers or
drivers. The only signiﬁcant result was a depletion of predisposi-
tion variants in cluster 4H, which is characterised by diffuse
perturbations in DNA replication (Fig. 3a). Interestingly, the 54
cancer predisposition genes damaged in EAC patients are
enriched in DNA repair pathways (FDR= 2.3 × 10–10, Fisher’s
exact test). It is tempting to speculate that germline damages
affecting DNA repair pathways would render additional somatic
perturbations in the same pathways lethal and therefore be
counter-selected.
Finally, we checked whether patient clustering is affected by the
number of helper genes considered in each patient. We
performed the same analysis considering the top ﬁve or top
15 scoring genes (528 and 1297 unique genes, respectively). We
found that the vast majority (99 and 77%) of the pathways
enriched in these datasets are also enriched when considering the
top 10 helpers (Supplementary Fig. 8), indicating that the
recurrently perturbed processes are highly overlapping. We then
clustered EACs according to the proportion of shared perturbed
pathways and veriﬁed that the six clusters obtained using
pathways enriched in top 10 genes recapitulated well the clusters
obtained using top ﬁve or 15 genes (Supplementary Fig. 8).
Therefore, the clustering is robust regardless of the applied
ranking cut-off.
Helper alterations lead to cancer phenotypes and dependence.
To test the contribution of EAC helper genes to cancer, we
used two experimental approaches. In the ﬁrst approach, we
assessed the consequences of altering (1) frequently or rarely
altered helpers; (2) loss of function alterations or gain of function/
overexpression; and (3) processes that deﬁne speciﬁc helper
clusters or that are altered across all helper clusters. We used
diploid EAC FLO-1 cells that have no alterations in any of the
helpers selected for validation14 to allow a clear evaluation of the
effect of their induced alteration. We measured cell proliferation
as a main hallmark of cancer3 and also performed gene-speciﬁc
assays. In the second approach, we evaluated the dependence of
EAC on helper perturbations by assessing the effect of reverting
their alterations on cell growth. For this, we used EAC cell lines
with alterations similar to those observed in patients.
First, we modiﬁed the most commonly altered helpers in
clusters 2H and 4H, E2F1 (23 out of 24 samples in cluster 2H)
and MCM7 (18 out of 37 samples in cluster 4H, Supplementary
Data 1). Both E2F1 and MCM7 are ampliﬁed in EACs
(Supplementary Data 3) leading to signiﬁcant gene overexpres-
sion (median two-fold increase, p= 6 × 10–3 and p= 8 × 10–3,
respectively, Wilcoxon rank-sum test; Fig. 4a). We therefore
overexpressed E2F1 and MCM7 in FLO-1 cells to levels
comparable to those observed in patients (Fig. 4b). In both cases,
this resulted in signiﬁcantly increased proliferation of over-
expressing cells compared to control cells (p= 2 × 10–4 and p=
9 × 10–4, respectively, two-tailed t-test; Fig. 4c). Since E2F1
promotes cell cycle progression, we assessed DNA replication rate
by EdU incorporation. We observed increased EdU intensity
throughout S phase in E2F1 overexpressing cells compared to
control cells (p < 10–4, Mann Whiney U test; Fig. 4d). This
suggests that E2F1 may help cancer growth by promoting S
phase entry. To assess the consequence of MCM7 overexpression,
we measured the loading of the MCM complex onto chromatin.
MCM7 overexpressing cells display a lower MCM
ﬂuorescence intensity overall compared to control cells when
staining the chromatin-bound fraction for either MCM7 or
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MCM3 (p < 10–4, Mann–Whitney U test; Fig. 4e, f). This suggests
that less MCM complex is loaded onto chromatin by the start of S
phase. Therefore, MCM7 overexpression leads to both increased
proliferation and perturbation of MCM complex activity. Finally,
we reduced MCM7 expression levels in MFD-1 cells derived from
one of our EAC patients29. MFD-1 cells have four-fold higher
MCM7 basal expression compared to FLO-1 cells (Fig. 4g). We
therefore used a doxycycline-inducible shRNA lentiviral vector
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(Supplementary Table 3) to reduce MCM7 expression in MFD-1
cells to the level of FLO-1 cells (Fig. 4h). This led to a signiﬁcant
decrease in proliferation (p= 2 × 10–5, two-tailed t-test; Fig. 4i),
indicating that MFD-1 cells rely on MCM7 overexpression for
their growth.
Next, we evaluated the role of rarely altered helpers, such as
NCOR2 that is altered in eight EACs across ﬁve of the six clusters
(Supplementary Data 3). NCOR2 contributes to the nuclear
receptor corepressor complex that favours global chromatin
deacetylation and transcriptional repression5,30 (Fig. 5a).
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Consistently with the suggested tumour suppressor role of
NCOR2 in lymphoma and prostate cancer31, the most frequent
NCOR2 alterations in EAC lead to a loss of function. To
reproduce these alterations, we edited NCOR2 in FLO-1 cells
using a vector-free CRISPR system32 (Methods, Supplementary
Table 3) and the editing was quantiﬁed using MiSeq (Fig. 5b). We
observed a 1.3-fold increase in proliferation of edited cells
compared to the control cells (p= 3 × 10–3, two-tailed t-test test;
Fig. 5c).
Then, we tested the effect of altering members of the Rho
GTPase effector pathway, pervasively perturbed in all six clusters,
often through patient-speciﬁc alterations (Fig. 5d, Supplementary
Data 1). We modiﬁed ABI2 and PAK1, which undergo damaging
alterations and ampliﬁcation in one and nine EACs, respectively
(Supplementary Data 3). We therefore edited ABI2 and over-
expressed PAK1 as described above (Supplementary Table 3,
Fig. 5e) and observed signiﬁcantly increased proliferation
compared to control cells (ABI2: p= 4 × 10–4, PAK1: p= 1 ×
10–3 two-tailed t-test; Fig. 5f).
Finally, we focussed on PSMD3 encoding a subunit of the
regulatory 19S proteasome complex. PSMD3 is ampliﬁed and
overexpressed in three EACs of cluster 1H, which overall
contains 14 samples with alterations in six proteasome subunits
(Fig. 6a and Supplementary Data 3). Three EAC cell lines
(MFD-1, OE19 and OE33) show higher basal expression of
PSMD3 compared to FLO-1 (2-, 3- and 4-fold increase
respectively, Fig. 6b). Using a doxycycline-inducible lentiviral
shRNA vector (Supplementary Table 3), we reduced PSMD3
expression in MFD-1, OE19 and OE33 cells to levels equivalent
to those of FLO-1 (Fig. 6c). In all three cell lines we observed a
signiﬁcant reduction in cell proliferation following the reduc-
tion of PSMD3 expression (MFD-1: p= 4 × 10–8; OE19: p= 2 ×
10–8; OE33: p= 6 × 10–3, two-tailed t-test; Fig. 6d). The effect
was particularly strong in OE19, where cell growth was arrested
completely. MFD-1 and OE33 showed 1.3- and 1.2-fold
reductions in cell growth (Fig. 6d). This suggests that the
extent of EAC reliance upon helper alterations is at least
partially context dependent.
Taken together, our experimental data indicate that, indepen-
dently of the alteration frequency, the modiﬁcation of helpers
positively affects EAC cell growth. The fold changes
in proliferation rate observed upon perturbation of helpers are
in the same range as those observed following alteration of known
strong drivers including TP53 or PIK3CA33,34. Moreover, we
provide evidence that EAC cells become addicted to helper
alterations, suggesting that targeting helpers, or the pathways in
which they act, could reduce EAC progression.
Helper alterations promote growth in Barrett’s esophagus. To
evaluate the role of helper perturbations in the early stages of
EAC, we quantiﬁed their alterations in 82 samples of Barrett’s
esophagus (BE)35, a pre-malignant condition associated with
EAC. When considering both damaging and non-damaging
alterations, the percentages of helpers and known drivers14
altered in the whole BE cohort were comparable to that of cancer-
unrelated genes (Fig. 7a). However, when considering only
damaging alterations, helpers showed signiﬁcant enrichment
compared to the rest of genes (p= 4 × 10–13 and p= 3 × 10–6,
respectively, Fisher’s exact test; Fig. 7b). Early alteration of helpers
in pre-malignant lesions suggests that they may favour the
transition to cancer. To further validate this hypothesis, we
altered representative helpers in BE CP-A cells and evaluated the
impact of their alterations on cell growth. As already reported6,35,
damaging point mutations were the most common alterations in
BE (Fig. 7c). Therefore, we edited ABI2 and NCOR2 to mimic
their putative loss-of-function alterations. Since CP-A cells have
wild-type TP5336, we also edited TP53 to compare the effect of
altering helpers to that of altering a strong driver. After con-
ﬁrming high editing levels (Fig. 7d), we observed a signiﬁcant
increase in cell proliferation compared to control cells in all three
cases (ABI2: p= 3 × 10–4, NCOR2: p= 1 × 10–2, TP53: p= 1 ×
10–4, two-tailed t-test; Fig. 7e). Strikingly, both helpers promote
cell growth to comparable levels to TP53, suggesting that helper
alterations can favour early cancer progression to a similar extent
to driver alterations.
Discussion
Most state-of-the-art approaches to discovering cancer driver events
rely on the detection of positively selected alterations of genes that
promote cancer development3,19. Even ratiometric methods based
on gene properties37 ultimately assess the effect of positive selection
and distinguish the few selected drivers from the many passenger
events. As a result, the discovery of cancer drivers is biased towards
frequently altered genes, with signiﬁcant limitations for cancers
such as EAC that have a highly variable but mostly ﬂat (i.e. with few
recurrent events) mutational landscape. Indeed, the overall selection
acting on esophageal cancer genomes is among the lowest across
cancer types19, despite a median of 382 damaged genes per EAC
(Supplementary Data 1). Therefore, the exclusive focus on genes
under strong selection is likely to return only a partial representa-
tion of the genes involved in EAC.
To overcome these limitations, our machine learning approach
sysSVM ranks somatically altered genes relevant to cancer
development based on their properties rather than mutation
recurrence. sysSVM also considers all types of gene alterations
Fig. 4 Cancer helper role of E2F1 and MCM7. a E2F1 and MCM7 expression in EACs with ampliﬁcation (n= 11 samples each) compared to copy number
neutral EACs (n= 81 samples each). Signiﬁcance was assessed by Wilcoxon rank-sum test. b E2F1 and MCM7 mRNA expression in FLO-1 cells. Lower and
upper hinges and middle line of boxplots correspond to 25th, 75th, and 50th percentiles. Upper and lower whiskers extend less than 1.5 times the
interquartile range. c Proliferation of FLO-1 cells overexpressing E2F1 or MCM7 compared to control. d. EdU (5-ethynyl-2′-deoxyuridine) incorporation by
ﬂow cytometry in E2F1 overexpressing cells compared to control. Cells were separated into G1, S and G2 phases. S phase cells were subdivided into 4 gates
(S1-S4, Supplementary Fig. 9). Differences in EdU geometric mean ﬂuorescence intensity were assessed by Mann-Whitney U test. MCM complex loading
onto chromatin in MCM7 overexpressing or control cells through MCM7 e or MCM3 f staining. Cells were pulsed with EdU and chromatin was fractioned
before staining for MCM7 or MCM3 to detect chromatin-bound MCM complex. Cells were separated into cell cycle phases using EdU and DAPI intensity.
MCM7 or MCM3 ﬂuorescence intensity during S phase illustrates MCM complex unloading from chromatin. Differences in geometric mean ﬂuorescence
intensity of MCM staining were assessed using Mann-Whitney U test. For (d), (e), (f) one representative of n= 3 biological replicates is shown.
Corresponding pseudocolour plots are in Supplementary Fig. 9. g MCM7 mRNA expression in MFD-1 and FLO-1 cells. h qRT-PCR MCM7 expression in
MFD-1 cells after transduction with a MCM7-shRNA inducible lentiviral vector. Expression was assessed with or without 96 h doxycycline treatment. i
Proliferation curve of MFD-1 cells with or without doxycycline-induced MCM7 knockdown. For all qRT-PCR experiments, expression was relativised to β-2-
microglobulin and normalised to FLO-1 cells. N= 2 biological replicates were performed, each in technical triplicate. For all proliferation assays, n= 2
biological replicates were performed, each with four technical replicates. Proliferation was assessed every 24 h and normalised to time zero. Mean values at
72 h were compared by two-tailed Student’s t-test. Error bars show standard deviation. Source data are available in the Source Data ﬁle
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(SNVs, indels, CNVs, and structural variations) simultaneously,
providing a comprehensive overview of the genetic modiﬁcations
with a cancer role in individual patients. When applied to 261
EACs, sysSVM prioritises 952 altered genes that, together with
known drivers, help cancer progression. The large number
reﬂects the positive correlation between mutational burden and
number of driver genes, which is only partially explained by a
sample size effect3. This positive correlation may indicate that the
number of functionally relevant genes increases with the number
of altered genes.
The heterogeneous landscape of EAC is substantially reduced
by considering the perturbed biological processes (Fig. 2c). Most
of these processes are well-known contributors to cancer devel-
opment, including intracellular signalling, cell cycle control, and
DNA repair (Supplementary Data 4). Interestingly, while the
known drivers tend to encode upstream players in these path-
ways, helpers are often downstream effectors. For example, we
found several Rho GTPase effectors (Fig. 5d, Supplementary
Data 3) or genes downstream of previously reported EAC drivers
in the Toll-like receptor cascade (Supplementary Data 3). This
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supports a more local role of helpers in contributing to cancer at
the single patient level, through sustaining or complementing
driver functions. In this respect, helpers are conceptually similar
to mini-drivers38.
Clustering pathways disrupted by helpers allows the division
of the 261 EACs into six clusters that are often functionally
related. For example, clusters 1H and 3H share perturbations in
intracellular signalling. Similarly, clusters 2H and 4H show
perturbations in cell cycle regulation, including S phase entry
and DNA replication. Consistent with this, they bring together
the most genomically unstable samples. By experimentally
mimicking the ampliﬁcation of E2F1 (representative of cluster
2H) and MCM7 (representative of cluster 4H), we increased
proliferation in EAC cells (Fig. 4c). We also provide evidence
that E2F1 increases proliferation by promoting S phase entry
(Fig. 4d). Interestingly, MCM7 overexpression reduced MCM
complex loading onto chromatin (Fig. 4e, f), maybe due to a
stoichiometric imbalance of complex subunits. This may indi-
cate that MCM7 promotes cell growth through a separate
mechanism besides its function in the MCM complex. For
example, MCM7 interacts with the tumour suppressor protein
Rb, a well-characterised inhibitor of E2F139. It is possible that
MCM7 overexpression may sequester Rb away from E2F1,
thereby promoting E2F1-mediated cell cycle progression.
Moreover, reducing MCM7 expression in cells with high basal
expression led to decreased cell proliferation, showing the
dependence of cancer cells on this alteration.
We also conﬁrmed the cancer promoting role of very rare
helpers, including ABI2, NCOR2 and PAK1 that are altered in
1–4% of EACs (Fig. 5c–f). Therefore, irrespective of the frequency
across patients, helpers have a substantial impact on cancer
progression. We therefore speculate that it is the contribution of
several genes perturbing the same pathways that promotes cancer
progression rather than the alteration of one gene alone. In line
with this, the dysregulation of a strong driver such as TP5333 or
PIK3CA34 alone does not have a dramatic effect. This is con-
ﬁrmed by our data where the alteration of one helper gene has a
mild yet signiﬁcant effect on cell proliferation. Interestingly,
helpers are also frequently altered in pre-cancerous lesions known
as Barrett’s esophagus (Fig. 7b), indicating that their alteration
may be an early event in EAC transformation. Consistent with
this, the perturbation of helpers leads to increased proliferation in
BE cells and the effect is comparable to that of perturbing TP53
(Fig. 7e).
The expansion of the repertoire of cancer genes may indicate
new, patient-speciﬁc gene dependencies suggesting possible
stratiﬁcations that could inform the selection of targeted treat-
ments. For example, 14 samples of cluster 1H have alterations of
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several proteasome subunits (Fig. 6a, Supplementary Data 1).
Experimentally reverting the expression of the proteasome sub-
unit PSMD3 to diploid levels reduced proliferation in three dif-
ferent EAC cell lines (Fig. 6d), suggesting that EACs become
addicted to helper alterations and vulnerable to their inhibition.
Interestingly, proteasome inhibition has been shown to have a
synergic effect in combination with ERBB2 inhibitors40. Since
ERBB2 is also signiﬁcantly altered in cluster 1H (Fig. 2d), a
combined therapy may be beneﬁcial to patients in this cluster.
In summary, we provide an attempt to extend the discovery of
acquired perturbations contributing to cancer beyond those of
recurrent drivers. Additional efforts are required to fully exploit
the potential of these approaches to offer a more comprehensive
view of the molecular mechanisms behind cancer and to guide
clinical interventions.
Methods
Annotation of molecular properties. Data on somatic single nucleotide variations
(SNVs), small insertions and deletions (indels), copy number variations (CNVs),
structural variations (SVs), and mutational signatures for 261 EACs were obtained
from ICGC and analysed as previously described16 (Supplementary Data 1).
Brieﬂy, SNVs and indels were called using Strelka v.1.0.1341 and subsequently
ﬁltered16. For CNVs, the absolute copy number for each genomic region was
obtained from ASCAT-NGS v.2.142 after correction for tumour content, using read
counts at germline heterozygous positions as derived from GATK v.3.2–243. To
account for the high number of ampliﬁcations occurring in EAC, copy number
gains were corrected by the ploidy of each sample as estimated by ASCAT-NGS. A
gene was assigned with the copy number of a CNV region if at least 25% of its
length was contained in that region. SVs (gene translocations, inversions, inser-
tions) were identiﬁed from discordant read pairs using Manta44 after excluding SVs
that were also present in more than two normal samples of a panel of 15 esophagus
and 50 blood samples16. In the case of the TCGA validation cohort, SNVs, indels,
and CNVs were derived from level 3 TCGA annotation data of 86 EACs (Sup-
plementary Data 1). In the case of 21 EACs from a previous study17, SNVs, indels,
and CNVs were called as described for the ICGC samples (Supplementary Data 1).
The distribution of variant allele frequency of SNVs and indels across all samples
was used to remove outliers likely indicating sequencing or calling artefacts.
Variants with < 10% frequency and indels longer than ﬁve base pairs were also
removed. For CNVs, genomic regions were considered as ampliﬁed or deleted if
their segment mean was higher than 0.3 or lower than −0.3, respectively, capping
the segment mean to 1.5 to avoid hypersegmentation45. A gene was considered as
ampliﬁed or deleted if at least 25% of its length was contained in a CNV region and
the resulting copy number (CN) was estimated as:
CN ¼ 2 ´ 2segment mean ð1Þ
No SV data were available for the validation cohorts.
Since only genes with predicted damaging alterations were used as input for
sysSVM, further annotation for the variant damaging effect was performed.
Stopgain, stoploss, frameshift, nonframeshift, nonsynonymous, and splicing SNVs
and indels were annotated using ANNOVAR (December 2015)46. All truncating
alterations (stopgain, stoploss, and frameshift mutations) were considered as
damaging. Nonframeshift and nonsynonymous mutations were considered as
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Fig. 7 Effect of helper alterations in Barrett’s esophagus cells. a Percentages of altered helper genes (661/952), known cancer genes (364/518) and rest of
cancer unrelated genes (12,250/17,544) over the corresponding total. b Percentages of damaged helper genes (261/952), known cancer genes (135/518)
and rest of cancer unrelated genes (3,093/17,544) over the corresponding total. Statistical signiﬁcance was assessed with two-tailed Fisher’s exact test.
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(Methods) with the exception of gene gains. In this case, only ‘high gains’ deﬁned as in the original publication35 were considered as damaging. d Editing of
ABI2, NCOR2 or TP53 in CP-A cells through nucleofection of two crRNAs and Cas9 protein. The editing efﬁciency was measured by MiSeq and quantiﬁed as
described above. For all three genes, a single amplicon was sequenced. NCOR2, ABI2 and TP53 crRNAs overlapped for over 70% of their sequences and
therefore it was not possible to assess their editing efﬁciency independently. e Proliferation curves of CP-A cells after ABI2, NCOR2 or TP53 editing
compared to control cells. For all proliferation experiments, n= 3 biological replicates were performed, each with four technical replicates. Proliferation was
assessed every 24 h and each time point was normalised to time zero. Mean values at 72 h were compared by two-tailed Student’s t-test. Error bars show
standard deviation. Source data are available in the Source Data ﬁle
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non-truncating damaging alterations if predicted by at least ﬁve of seven function-
based methods (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, MutationTaster,
MutationAssessor, LRTand FATHMM) or by two out of three conservation-based
methods (PhyloP, GERP++ RS, SiPhy), using the scores from dbNSFP v.3.047.
Splicing modiﬁcations were considered as damaging if predicted by at least one of
the two ensemble algorithms as implemented in dbNSFP v3.0. Putative gain of
function alterations were predicted with OncodriveClust48 with default parameters
and applying a false discovery rate of 10%. The transcript lengths to estimate
mutation clustering were derived from the refGene table of UCSC Table Browser
(https://genome.ucsc.edu/cgi-bin/hgTables). Gene gains, homozygous losses,
translocations, inversions, insertions were always considered as putative damaging
alterations.
Overall, 17,078 genes had at least one damaging alteration, for a total of 116,989
redundant damaged genes across 261 EACs (Supplementary Table 1). Of these, 476
were known cancer genes14, corresponding to 4091 redundant genes
(Supplementary Data 1). For all 17,078 genes, the total number of exonic
alterations (silent and nonsilent) and the somatic copy number were used as
additional molecular features in sysSVM.
Annotation of systems-level properties. Protein sequences from RefSeq v.6349
were aligned to the human reference genome assembly GRCh37 to deﬁne unique
gene loci10. The length of the longest coding sequence was taken as the gene
length. Genes aligning to more than one gene locus for at least 60% of the
protein length were considered as duplicated genes11. Data on human ohnologs
(gene duplicates retained after whole genome duplications) were collected from
Makino et al.50. The number of protein domains was derived from CDD51. The
gene chromatin state based on Hi-C experiments13 was retrieved from the
covariate matrix of MutSigCV v1.2.012. Data on protein-protein and miRNA-
gene interactions, gene evolutionary origin and gene expression were retrieved as
described in An et al.10. Brieﬂy, the human protein-protein interaction network
was rebuilt from the integration of BioGRID v.3.4.125;52 MIntAct v.190;53 DIP
(April 2015);54 HPRD v.9;55 the miRNA-gene interactions were derived from
miRTarBase v.4.556 and miRecords (April 2013);57 gene evolutionary origin was
assessed as described in D’Antonio et al.12 using gene orthology from EggNOG
v.4;58 and gene expression in 30 normal tissues was retrieved from GTEx
v.1.1.859. Except gene length, duplication and ohnologs, all other systems-level
properties had missing information for some of the 17,078 altered genes (Sup-
plementary Table 1). To account for this, median imputation for continuous
properties and mode imputation for categorical properties were implemented.
Speciﬁcally, for each property median or mode values were calculated for known
cancer genes and the rest of mutated genes. All missing values were replaced
with their corresponding median or mode values.
Application of sysSVM to EACs. The three steps of sysSVM were applied to 261
EACs (Fig. 1a, b, Supplementary Note 1). In step 1, all 34 features derived from
molecular and systems-level properties (Supplementary Table 1) were mapped to
the 17,078 altered genes in the cohort. Each feature was scaled to zero mean and
unit variance to correct for the different numerical ranges across them. In step 2,
476 known cancer genes with damaging alterations (Supplementary Data 2) were
used as a set of true positives for model selection. To optimise the parameters of the
four kernels (linear, radial, sigmoid and polynomial) a grid search using 10,000
iterations of a three-fold cross validation was performed. At each iteration, the 476
known cancer genes were randomly split into 2/3 (around 317 genes) used as a
training set and 1/3 (around 159 genes) used as the test set. At each increment of
100 cross validation iterations, the four best models (one per kernel) were chosen
based on the median and variance of the sensitivity distribution across all previous
iterations of cross-validation. The selection of the 100 sets of best models from all
10,000 cross-validation iterations was repeated 5 times, where all iterations were
randomly re-ordered. In step 3, the resulting 500 best models were trained with the
whole training set and used to rank the remaining 16,602 unique genes in each
patient. A score was measured to combine the predictions from the four kernels
and the genes not expressed in normal esophagus according GTEx annotation were
excluded. These produced 500 lists of top 10 genes. Out of 500 best models, 38 had
a unique set of parameters resulting in 24 unique lists of top 10 genes (Supple-
mentary Table 2). These 24 lists ranged between 898 and 952 genes, with a core set
of 598 genes shared across all of them. The most frequent top 10 list occurred 207
times (952_A, 41.4%, Supplementary Table 2). It was followed by 952_B (32.2%,
161 times) and 951_A (8.6%, 43 times). These three lists accounted for 82.2% of the
500 sets of top 10 genes, they shared 950 genes and were predicted by models
differing in only one parameter (gamma in the polynomial kernel, Supplementary
Table 2). Furthermore, the most frequent list was always predicted by the same set
of best models. Therefore, 952_A represented a robust set of prediction and was
considered as the ﬁnal list of helper genes (Supplementary Data 3). To quantify the
relative contribution of the 34 features to the four best models used to predict
the ﬁnal set of helper genes in the 952_A ﬁnal list, Recursive Feature Elimination
(RFE)15 was implemented. RFE ﬁrst deﬁnes the best set of parameters for each
kernel. Secondly, RFE trains the one-class classiﬁer in each kernel and computes
the weight (w) of each feature, deﬁned as the product of the sysSVM coefﬁcients
with each support vector. Thirdly, RFE ranks the features according to w2 and
recursively removes the feature with the smallest value of w2 until no feature
remains. In the case of sysSVM this was done 34 times until all sysSVM features
were ranked (Supplementary Fig. 3).
Identiﬁcation of perturbed processes and patient clustering. To identify the
perturbed biological processes in the EAC cohort, both predicted cancer helper
genes and known cancer genes were used. A manual revision of 476 known cancer
genes altered in the ICGC cohort was performed and genes were considered as
known drivers if (a) their somatic alteration had been previously associated with
EAC, (b) they had a loss-of-function alteration and their tumour suppressor role
had been reported in other cancer types60, (c) they had a gain-of-function
alteration and their oncogenic role had been reported in other cancer types60. The
resulting 202 known cancer drivers (Supplementary Data 2) and 952 cancer helpers
were used for the gene set enrichment analysis against Reactome v.5861, composed
of 1877 pathways and 10,131 genes. After excluding pathways in levels 1 and 2 of
Reactome hierarchy and those with less than 10 or over 500 genes, 1155 pathways
were retained. These contained 9061 genes, including 155 known drivers and 648
helpers. Gene set enrichment was assessed using a one-sided hypergeometric test
and the resulting P values were corrected for multiple testing using the Benjamini
& Hochberg method (Supplementary Data 4). Enriched pathways within the sets of
known drivers or helpers were subsequently used to cluster samples taking into
account the proportion of perturbed processes shared between samples. The Jac-
card index (A) was calculated by deriving the proportion of shared perturbed
processes between all possible sample pairs as:
Aij ¼ Pi \ Pj





= Pi ∪ Pj





 ð2Þ
where Pi and Pj are the perturbed processes in samples i and j, respectively.
Complete linkage hierarchical clustering using Euclidean distance between each
row was performed on the resulting matrix. Clusters were visualised using
ComplexHeatmap R package62. To identify the optimal number of clusters, the
median silhouette value of the samples for between 3 and 20 clusters was measured
as a measure of clustering robustness63.
Annotation of germline variants. Starting from germline variants (SNVs and
indels)16, a series of ﬁlters were applied. First, heterozygous calls with Variant
Allele Frequency (VAF) deviating from 50% by more than 2.6 standard deviations
and homozygous calls with VAF less than 95% were removed. Second, variants
were removed if their Minor Allele Frequency (MAF) in EACs was > 10% and
substantially larger than in ExAC64 and in the European cohort from 1000 Gen-
omes27 using the following formula:
MAFEAC >
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
10 ´MAFreference
q
ð3Þ
were MAFreference was the MAF in ExAC or 1000 Genomes.
Finally, variants were also removed if they exhibited an excess of heterozygosity
determined as:
pAa > 1:04
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1:04 3:74 ´ pA ´ pa
p ð4Þ
where pAa, pA and pa are the proportion of heterozygote variants, the major allele
frequency and the minor allele frequency respectively. This formula was
empirically chosen based on the principle of Hardy-Weinberg equilibrium65. The
resulting variants were considered damaging if they were frameshift indels,
introduced stopgains or stoplosses, or if deﬁned damaging in at least ﬁve out of
seven functional predictors as described above. Only rare damaging variants (MAF
< 1% in ExAC64 and in the Europeans from 1000 Genomes27) were further
retained. A list of 152 cancer predisposition genes was obtained from the
literature26. EAC patients that carried a rare damaging germline variant in one of
these genes were considered to carry a cancer predisposition variant.
Analysis of RNA sequencing data. Puriﬁed total RNA was extracted from 92
EACs from the ICGC cohort and sequenced16. RNA sequencing reads were then
aligned to human reference genome hg19 and expression values were calculated
using Gencode v19. The summarise Overlaps function in the R GenomicAlign-
ments package was used to count any fragments overlapping with exons (para-
meters mode=Union, singleEnd, invertStrand and inter.feature were set according
to the library protocol, fragments= TRUE, ignore.strand= FALSE). Gene length
was derived as the number of base pairs in the exons after concatenating the exons
per gene in non-overlapping regions. FPKM (Fragments Per Kilobase Million) were
calculated for each gene as:
FPKM ¼ gene read countðlibrary size=1000000Þ ´ ðgene length=1000Þ ð5Þ
Cell lines. Overexpression and editing experiments were carried out using the
FLO-1 esophageal adenocarcinoma cell line obtained from the ECACC General
Cell Collection and CP-A (KR-42421) Barrett’s Esophagus cells from ATCC
(catalogue number CRL-4027). FLO-1 cells were grown at 37 °C and ﬁve per cent
CO2 in DMEM+ 2 mM Glutamine+ 10% FBS (Biosera)+ 1/10,000 units of
penicillin–streptomycin. CP-A cells were grown at 37 °C and ﬁve per cent CO2
in Keratinocyte serum-free medium with 50 µg ml−1 bovine pituitary extract and
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5 ng ml−1 recombinant human EGF (17005042, Thermo Fisher). For passaging of
CP-A cells, 250 mg L−1 soybean trypsin inhibitor in PBS was used (17075029,
Thermo Fisher). Gene knockdown experiments were performed on OE19 cells
obtained from the Francis Crick Institute cell services, OE33 cells obtained from
the ECACC General Cell Collection and MFD1 cells obtained from the OCCAMS
Consortium. OE19 and OE33 cells were grown in RPMI+ 2 mM Glutamine+ 10%
FBS (Biosera)+ 1/10,000 units of penicillin–streptomycin. MFD1 cells were grown
in DMEM+ 2 mM Glutamine+ 10% FBS (Biosera)+ 1/10,000 units of
penicillin–streptomycin. All cells were maintained at 37 °C and ﬁve per cent CO2,
validated by short tandem repeat analysis and routinely checked for mycoplasma
contamination.
Gene overexpression. The vectors pCMVHA E2F166 (Item ID 24225, Addgene),
pLX_TRC317 (TRCN0000481188, Sigma-Aldrich) and pcDNA3.1+ /C-(K)-DYK
(Clone ID: OHu19407D, Genscript) were used to induce E2F1, MCM7, and PAK1
overexpression, respectively. FLO-1 cells were transfected according to the man-
ufacturer’s protocol, while CP-A cells were nucleofected following the Neon™ kit
protocol (Thermo Fisher), with 2 pulses of 1200 V for 20 ms. Overexpressing cells
were selected with either G481/Geneticin (E2F1, PAK1) or Puromycin (MCM7).
Empty vectors carrying G418 (pcDNA3.1+ /C-(K)-DYK, Genscript) or Puromycin
(Item ID 85966, Addgene) resistance were used as controls. The RNA from
transfected cells was used to assess gene overexpression via quantitative RT-PCR
using predesigned SYBR green primers (Sigma-Aldrich; Supplementary Table 3)
and Brilliant III Ultra-Fast SYBR Green QRT-PCR Master Mix (Agilent Tech-
nologies). The average expression level across triplicates (e) was relativised to the
average expression level of β-2-microglobulin (c):
r ¼ e c ð6Þ
where r is the relative gene expression. The fold change (fc) between the relative
gene expression after overexpression and the relative gene expression in the control
condition (rc) was calculated as:
fc ¼ 2 rcrKDð Þ ð7Þ
Each sample was assessed in triplicate and each experiment was repeated in
biological duplicate.
Gene editing. To induce ABI2 and NCOR2 gene knock-out (KO) in FLO-1 cells,
the vector-free CRISPR-mediated editing approach was used as previously
described32. Brieﬂy, cells were co-transfected using lipofectamine CRISPR max
(Life technologies) with a 69-mer tracrRNA (Sigma-Aldrich), three gene-speciﬁc
crRNAs (Sigma-Aldrich, Supplementary Table 3) and GeneArt Platinum Cas9
nuclease (Life technologies). To avoid off-target editing, all crRNAs used were
veriﬁed to map only the gene of interest with a perfect match and additional hits in
the genome with at least three mismatches. Control cells were transfected with the
same protocol but using three non-targeting crRNAs. In CP-A cells, vector-free
CRISPR-mediated editing of ABI2, NCOR2 or TP53 was performed by introducing
two gene-speciﬁc crRNAs (Synthego, Supplementary Table 3) and GeneArt Pla-
tinum Cas9 nuclease (Life technologies) into the cells by nucleofection following
the Neon™ kit protocol (Thermo Fisher), with 2 pulses of 1200 V for 20 ms. In all
cases, gene editing was conﬁrmed with Illumina MiSeq sequencing. The regions
surrounding the targeted sites were ampliﬁed from genomic DNA of edited cells
with primers containing Illumina adapters (Supplementary Table 3) using Q5 Hot
Start High-Fidelity 2× Master Mix (New England Biolabs). DNA barcodes were
added with a PCR reaction before pooling the samples for sequencing on Illumina
MiSeq with the 250 base-pair paired-end protocol. Sequencing reads were merged
into single reads and aligned to the human reference genome hg19 using BBMerge
and BBMap functions of BBTools67, obtaining an average of 78,864 aligned reads
per experiment. SNVs and small indels in the regions corresponding to each
crRNA (Supplementary Table 3) were called using the CrispRVariants package in
R68 and the percentage of edited alleles was estimated as the percentage of variant
reads in each experiment.
Gene knockdown. Inducible gene knockdown was carried out using lentiviral
pTRIPZ-TurboRFP (MCM7) or pSMART-TurboGFP (PSMD3) shRNA vectors
(Dharmacon). For each gene, three shRNA vectors were tested (Supplementary
Table 3). Virus was produced by co-transfecting HEK293T cells with pTRIPZ or
pSMART constructs alongside psPAX2 and pMD2.G vectors (Addgene) using
Fugene HD (Promega). Viral supernatant was collected at 24 and 48 h and used for
two rounds of infection of OE19, OE33 or MFD1 cells, using 8 μg ml−1 hex-
adimethrine bromide (Sigma-Aldrich). Infected cells were selected after 48 h with 2
μg ml−1 puromycin for 7 days. To induce shRNA expression, cells were treated
with 1 μg ml−1 doxycycline (Sigma-Aldrich) for 16 h. Gene expression with or
without doxycycline was assessed by qRT-PCR using predesigned SYBR green
primers (Sigma-Aldrich; Supplementary Table 3). Cells with the highest level of
knockdown were then sorted by FACS to isolate medium expressing cells (the
middle 30% of cells based on TurboRFP or TurboGFP ﬂuorescence). Gene
expression after sorting was measured by qRT-PCR 24 h post-induction with 0–1
μg ml−1 doxycycline, to determine the concentration of doxycycline required to
reduce expression to levels equivalent to FLO-1 cells. The determined
concentrations of doxycycline used for proliferation assays were 0.05 μg ml−1 for
OE19 PSMD3 shRNA3, 0.25 μg ml−1 for OE33 PSMD3 shRNA3, 0.25 μg ml−1 for
MFD1 PSMD3 shRNA3, 0.75 μg ml−1 for MFD1 MCM7 shRNA3.
Cell proliferation. Cell proliferation was measured every 24 h for three or four
days, starting three hours after seeding the cells (time zero) using crystal violet
staining, CellTiter 96 Non-Radioactive Cell Proliferation Assay (Promega) or
CellTiter-Glo Luminescent Cell Viability Assay (Promega). Brieﬂy, 4.5 × 103 cells
per well were seeded on 96-well plates in a ﬁnal volume of 100 μl per well. For
inducible shRNA-expressing cells, doxycycline was added 48 h prior to the start of
the assay, and culture media replaced every 24–48 h with fresh media containing
doxycycline. For the CellTiter 96 Non-Radioactive Cell Proliferation Assay, 15 μl of
the dye solution was added into each well and cells were incubated at 37 °C for two
hours. The converted dye was released from the cells using 100 μl of the solubili-
sation/Stop solution and absorbance was measured at 570 nm after one hour using
the Paradigm detection platform (Beckman Coulter). For the CellTiter-Glo
Luminescent Cell Viability Assay, 100 μl of the CellTiter-Glo reagent was added
into each well and luminescence was measured after 30 min using the Paradigm
detection platform (Beckman Coulter). For all proliferation assays, four replicates
per condition were measured at each time point and each measure was normalised
to the average time zero measure for each condition. Each experiment was repeated
at least twice. Conditions were compared using the two-tailed Student’s t-test.
Flow cytometry. EdU incorporation and MCM loading were assessed using a
modiﬁed version of the protocol described in Galanos et al.69. Brieﬂy, in each
condition, 3 × 106 cells were pulsed for 30min with 10 µM EdU (Invitrogen) before
washing in 1% BSA/PBS. Chromatin fractionation was performed by incubating on
ice for 10min in CSK buffer (10mM HEPES, 100mM NaCl, 3 mM MgCl2, 1 mM
EGTA, 300mM sucrose, 1% BSA, 0.2% Triton-X100, 1 mM DTT, cOmplete EDTA-
free protease inhibitor cocktail tablets, Roche). Cells were then ﬁxed in 4% for-
maldehyde/PBS for 10min at room temperature before washing in 1% BSA/PBS.
Cells were permeabilised and barcoded70 by incubating in 70% ethanol containing
0–15 µgml−1 Alexa Fluor 488 (Thermo Fisher) for 15min, then washed twice in 1%
BSA/PBS. Barcoded cells were subsequently pooled before incubating in primary
antibody (mouse monoclonal anti-MCM7: Santa Cruz Biotechnology sc-56324, or
rabbit polyclonal anti-MCM3: Bethyl Laboratories A300–192A) diluted 1:100 in 1%
BSA/PBS for 1 h. After washing in 1% BSA/PBS, samples were incubated for 30min
in secondary antibody (Alexa Fluor 555-conjugated donkey anti-mouse: A-31570,
or donkey anti-rabbit: A-31572) diluted 1:500 in 1% BSA/PBS, then washed again in
1% BSA/PBS. EdU labelling with Alexa Fluor 647 azide was performed using Click-
iT EdU ﬂow cytometry assay kit (Invitrogen, C10424) following the manufacturer’s
instructions before washing samples in 1% BSA/PBS. Samples were then incubated
in 1% BSA/PBS containing RNase and 10 mgml−1 DAPI for 15 min before ana-
lysing with a BD LSR II Fortessa ﬂow cytometer (BD Biosciences). Lasers and ﬁlters
used include: 407 nm laser with 450/50 bandpass ﬁlter; 488 nm laser with 505
longpass and 530/30 bandpass ﬁlters; 561 nm laser with 570 longpass and 590/30
bandpass ﬁlters; 640 nm laser with 670/14 bandpass ﬁlter. Compensation was
performed manually with single colour controls, using BD FACSDiva software (BD
Biosciences). FlowJo 10.3 software was used to analyse MCM loading onto chro-
matin and EdU incorporation. Cells were gated to remove debris using FSC-A/SSC-
A, then gated to isolate singlets using DAPI-H/DAPI-A (Supplementary Fig. 9). The
cells were then separated by gating the barcoded populations using 488-A/DAPI-A.
Cells were ﬁnally separated into cell cycle gates (G1, S1-4, G2) based on EdU-647-A
and DAPI-A (Supplementary Fig. 9), and the geometric mean ﬂuorescence intensity
was obtained for each channel (MCM-555 or EdU-647).
ETHICS. All subjects gave informed consent, and this study was registered
(UKCRNID 8880) and approved by the Institutional Ethics Committees, Cam-
bridgeshire 4 Research Ethics Committee (REC 07/H0305/52 and 10/H0305/1).
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
WGS and RNA sequencing data can be accessed at the European Genome-phenome
Archive using the accession numbers EGAD00001004775 and EGAD00001004776,
respectively. TCGA data can be accessed through dbGaP accession number phs000178.
v10.p8. Source data for Fig. 4–6 are provided as a Source Data ﬁle.
Code availability
sysSVM is distributed as an R package under R 3.4.0 at https://github.com/ciccalab/
sysSVM.
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